Return to News
29 May 2023

1st Patient Enrolled in IBIS!

Our very virst patient has been enrolled in the IBIS study!

This study explores the use of iberdomide, isatuximab, and dexamethasone triplet in treating functional high-risk MM patients (patients who relapse within the first 12 months of starting first line therapy). 

Click here for more information, or e-mail us at amarc@alfred.org.au.